TY - JOUR
T1 - Hemodynamic effects of glutathione-liganded binuclear dinitrosyl iron complex
T2 - Evidence for nitroxyl generation and modulation by Plasma Albumin
AU - Liu, Taiming
AU - Zhang, Meijuan
AU - Terry, Michael H.
AU - Schroeder, Hobe
AU - Wilson, Sean M.
AU - Power, Gordon G.
AU - Li, Qian
AU - Tipple, Trent E.
AU - Borchardt, Dan
AU - Blood, Arlin B.
N1 - Publisher Copyright:
Copyright © 2018 by The American Society for Pharmacology and Experimental Therapeutics.
PY - 2018/5
Y1 - 2018/5
N2 - Glutathione-liganded binuclear dinitrosyl iron complex (glut-BDNIC) has been proposed to be a donor of nitric oxide (NO). This study was undertaken to investigate the mechanisms of vasoactivity, systemic hemodynamic effects, and pharmacokinetics of glut-BDNIC. To test the hypothesis that glut-BDNICs vasodilate by releasing NO in its reduced [nitroxyl (HNO)] state, a bioassay method of isolated, preconstricted ovine mesenteric arterial rings was used in the presence of selective scavengers of HNO or NO free radical (NO•); the vasodilatory effects of glut-BDNIC were found to have characteristics similar to those of an HNO donor and markedly different than an NO• donor. In addition, products of the reaction of glut-BDNIC with CPTIO [2-(4-carboxyphenyl)-4,4,5-tetramethyl imidazoline-1-oxyl-3-oxide] were found to have electron paramagnetic characteristics similar to those of an HNO donor compared with an NO• donor. In contrast to S-nitroso-glutathione, which was vasodilative both in vitro and in vivo, the potency of glut-BDNIC–mediated vasodilation was markedly diminished in both rats and sheep. Wire myography showed that plasma albumin contributed to this loss of hypotensive effects, an effect abolished by modification of the cysteine-thiol residue of albumin. High doses of glut-BDNIC caused long-lasting hypotension in rats that can be at least partially attributed to its long circulating half-life of ∼44 minutes. This study suggests that glut-BDNIC is an HNO donor, and that its vasoactive effects are modulated by binding to the cysteine residue of plasma proteins, such as albumin.
AB - Glutathione-liganded binuclear dinitrosyl iron complex (glut-BDNIC) has been proposed to be a donor of nitric oxide (NO). This study was undertaken to investigate the mechanisms of vasoactivity, systemic hemodynamic effects, and pharmacokinetics of glut-BDNIC. To test the hypothesis that glut-BDNICs vasodilate by releasing NO in its reduced [nitroxyl (HNO)] state, a bioassay method of isolated, preconstricted ovine mesenteric arterial rings was used in the presence of selective scavengers of HNO or NO free radical (NO•); the vasodilatory effects of glut-BDNIC were found to have characteristics similar to those of an HNO donor and markedly different than an NO• donor. In addition, products of the reaction of glut-BDNIC with CPTIO [2-(4-carboxyphenyl)-4,4,5-tetramethyl imidazoline-1-oxyl-3-oxide] were found to have electron paramagnetic characteristics similar to those of an HNO donor compared with an NO• donor. In contrast to S-nitroso-glutathione, which was vasodilative both in vitro and in vivo, the potency of glut-BDNIC–mediated vasodilation was markedly diminished in both rats and sheep. Wire myography showed that plasma albumin contributed to this loss of hypotensive effects, an effect abolished by modification of the cysteine-thiol residue of albumin. High doses of glut-BDNIC caused long-lasting hypotension in rats that can be at least partially attributed to its long circulating half-life of ∼44 minutes. This study suggests that glut-BDNIC is an HNO donor, and that its vasoactive effects are modulated by binding to the cysteine residue of plasma proteins, such as albumin.
KW - Myography
KW - Nitrogen Oxides/metabolism
KW - Electron Spin Resonance Spectroscopy
KW - Rats
KW - Male
KW - Nitric Oxide Donors/pharmacology
KW - Glutathione/metabolism
KW - Serum Albumin/metabolism
KW - Vasodilation/drug effects
KW - Vasodilator Agents/pharmacology
KW - Animals
KW - Mesenteric Arteries/drug effects
KW - Antihypertensive Agents/pharmacology
KW - Female
KW - Ligands
KW - Sheep
KW - Iron/metabolism
KW - Hemodynamics/drug effects
UR - http://www.scopus.com/inward/record.url?scp=85045021610&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85045021610&partnerID=8YFLogxK
UR - https://www.mendeley.com/catalogue/c6b9e799-4a35-388a-a6f6-826aaa1d0782/
U2 - 10.1124/mol.117.110957
DO - 10.1124/mol.117.110957
M3 - Article
C2 - 29476040
SN - 0026-895X
VL - 93
SP - 427
EP - 437
JO - Molecular Pharmacology
JF - Molecular Pharmacology
IS - 5
ER -